Novartis AG ADR (NVS)vsPersonalis Inc (PSNL)
NVS
Novartis AG ADR
$160.32
-0.04%
HEALTHCARE · Cap: $303.67B
PSNL
Personalis Inc
$15.86
-0.63%
HEALTHCARE · Cap: $1.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 70921% more annual revenue ($57.36B vs $80.77M). NVS leads profitability with a 17.5% profit margin vs -147.7%. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
PSNL
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.8%
Fair Value
$95.76
Current Price
$160.32
$64.56 premium
Margin of Safety
-42.9%
Fair Value
$6.23
Current Price
$15.86
$9.63 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 34.3%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Revenue surging 76.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
Trading at 8.1x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : PSNL
The strongest argument for PSNL centers on Revenue Growth, Debt/Equity. Revenue growth of 76.6% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : PSNL
The primary concerns for PSNL are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVS profiles as a value stock while PSNL is a hypergrowth play — different risk/reward profiles.
PSNL carries more volatility with a beta of 2.36 — expect wider price swings.
PSNL is growing revenue faster at 76.6% — sustainability is the question.
NVS generates stronger free cash flow (4.8B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 27/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Personalis Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Personalis, Inc. is a global cancer genomics company. The company is headquartered in Menlo Park, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?